阅读说明：本技术 木犀草素在预防和治疗子宫内膜异位症药物中的应用 (Application of luteolin in medicine for preventing and treating endometriosis ) 是由 倪晓容 孙奋勇 胡国华 王隆卉 左玲 郭英 杨玲 杨艺娇 夏悦 彭霞 于 2020-07-27 设计创作，主要内容包括：本发明涉及木犀草素在预防和治疗子宫内膜异位症药物中的应用。本发明以纤维化作为治疗靶点,评估将木犀草素应用于大鼠子宫内膜异位症模型中具有抗纤维化作用。木犀草素应用大鼠子宫内膜异位症中,具有治疗异位病灶纤维化的效果。因此,本发明为中药单体木犀草素在预防和治疗子宫内膜异位症纤维化药物的应用提供了直接的实验证据。(The invention relates to application of luteolin in a medicine for preventing and treating endometriosis. The invention takes fibrosis as a treatment target, and evaluates that the luteolin applied to a rat endometriosis model has an anti-fibrosis effect. Luteolin can be used for treating endometriosis and fibrosis of ectopic focus. Therefore, the invention provides direct experimental evidence for the application of the traditional Chinese medicine monomer luteolin in the medicines for preventing and treating endometriosis fibrosis.)

1. Application of luteolin in medicine for preventing and treating endometriosis is provided.

2. The use according to claim 1, wherein luteolin is used in a medicament for the prevention and treatment of endometriosis fibrosis.

3. The use according to claim 1, wherein the luteolin inhibits endometrial fibrosis.

4. The use according to claim 1, wherein the luteolin inhibits the formation of endometriosis fibrosis.

5. The use according to any one of claims 1 to 4, wherein the luteolin is used alone or in the form of a pharmaceutical composition comprising luteolin, a pharmaceutically acceptable salt thereof or a prodrug thereof, and at least one of a pharmaceutically carrier, excipient, diluent, adjuvant and vehicle.

Technical Field

The invention relates to the technical field of medicines, in particular to application of luteolin in medicines for preventing and treating endometriosis.

Background

Endometriosis (EMs) refers to the process of repeated bleeding, injury and reparation of endometrial tissue outside the body of the uterus along with the periodic change of hormones, and further changes of microenvironment, which leads to the activation of fibrosis-related factors, fibroplasia and adhesion formation. Excessive fibrosis leads to scarring, chronic pain, and changes in tissue function, leading to clinical symptoms such as dysmenorrhea, pelvic pain, and infertility. Histologically, endometriosis is characterized by dense fibrous tissue surrounding the endometrial glands and interstitium. The main treatment method of western medicine is operation or taking hormone, such as the commonly used pseudopregnancy therapy and the pseudomenopause therapy can help patients to relieve the illness state to a certain extent, but the diseases are easy to recur, the adverse effects are many, the pregnancy is not good, the symptoms such as osteoporosis and menopause syndrome can appear, and the long-term application of the medicine is limited. However, to date, only a few studies have evaluated new candidate therapies for endometriosis-associated fibrosis. Therefore, the search for a treatment scheme which is accurate and stable in curative effect, small in side effect and easy for patients to accept becomes the key point and difficulty of modern research of the disease.

Luteolin is present in various Chinese herbal medicines in the form of glycoside. The luteolin is used as a natural flavonoid compound, and researches show that the luteolin not only can pass through carbon monoxide and other inflammatory factors and has anti-inflammatory activity; and the anti-tumor effect is generated by inhibiting the proliferation of tumor cells and inducing the apoptosis of the tumor cells; in addition, luteolin also has multiple pharmacological activities of relieving cough, resisting allergy, virus and oxidation; luteolin is widely applied to liver fibrosis treatment in recent years, for example, in the research effect of luteolin on treating liver fibrosis by people like Mengxin, etc., luteolin serving as a natural flavonoid compound is found to be capable of effectively degrading the a-smooth muscle actin and the mRNA level of type 1 collagen in liver tissues, inhibiting the activation of hepatic stellate cells and the synthesis of collagen and effectively relieving the liver fibrosis degree. In the anti-fibrosis effect of luteolin on hepatic stellate cells and hepatic fibrosis by targeting AKT/mTOR/p70S6K and TGF beta/Smad signaling pathways, the application of luteolin in a mouse fibrosis model induced by CCL4 by Lijie et al finds that administration of luteolin significantly reduces hepatic fibrosis and results in reduced expression of p-Smad2 and p-AKT, inhibits proliferation and migration of cells, and synthesis of collagen. Thus, luteolin prevents the progression of liver fibrosis through various mechanisms and has the potential of effectively treating liver fibrosis.

Chinese patent document CN103083310A discloses an application of luteolin in preparing an anti-ovarian-aging medicament. Chinese patent document CN111315376A discloses a substance and composition for use in the treatment of endometriosis and endometriosis-related symptoms. The invention relates to the use of luteolin 2- (3, 4-dihydroxyphenyl) -,5, 7-dihydroxy-4-chroman in a method for the treatment of endometriosis and symptoms thereof. However, no report is found about the application of the traditional Chinese medicine monomer luteolin in the medicines for preventing and treating endometriosis fibrosis at present.

Disclosure of Invention

The invention aims to provide application of luteolin in medicines for preventing and treating endometriosis, aiming at the defects in the prior art.

In order to achieve the purpose, the invention adopts the technical scheme that:

application of luteolin in medicine for preventing and treating endometriosis is provided.

Further preferred scheme: the luteolin is applied to the medicines for preventing and treating endometriosis fibrosis.

Further preferred scheme: the luteolin inhibits endometrial fibrosis formation.

Further preferred scheme: the luteolin inhibits the formation of endometriosis fibrosis.

Further preferred scheme: the luteolin can be used alone or in the form of a pharmaceutical composition comprising luteolin, a pharmaceutically acceptable salt thereof or a prodrug thereof, and at least one of a pharmaceutically carrier, excipient, diluent, adjuvant and vehicle.

The invention discloses application of luteolin in a medicine for preventing and treating endometriosis fibrosis. The invention takes fibrosis as a treatment target to evaluate whether the luteolin applied to a rat endometriosis model has an anti-fibrosis effect. The method comprises the following steps: constructing a rat endometriosis model by an autograft method, after 4 weeks of successful modeling, respectively taking the modeled rat model group, the gestrinone control group and the luteolin group for 4 weeks, and taking out ectopic lesions by laparotomy. The fibrosis degree is mutually confirmed by HE dyeing and massson dyeing, the expression condition of a fibrosis index a-SMA is detected by immunohistochemistry, and the anti-fibrosis effect of luteolin is evaluated. As a result: luteolin prevents the development of fibrosis in endometriosis. Luteolin could therefore potentially be used to develop a drug for the future treatment or prevention of endometriosis fibrosis.

The invention has the advantages that: at present, the research on endometriosis is mostly explored from the pathological features of destruction, such as inflammatory reaction, angiogenesis and cell proliferation, migration, adhesion, invasion and the like, but the research on endometriosis is rarely treated from the fibrosis perspective, the research on the formation mechanism of endometriosis fibrosis is also rarely carried out, and no specific and effective medicine is used for improving the fibrosis, so that the research on endometriosis safely and effectively inhibits endometriosis fibrosis and improves clinical symptoms, and the research has important clinical significance. The invention discloses application of luteolin in a medicine for preventing and treating endometriosis fibrosis. The invention takes fibrosis as a treatment target, and evaluates that the luteolin applied to a rat endometriosis model has an anti-fibrosis effect. Luteolin can be used for treating endometriosis and fibrosis of ectopic focus. Therefore, the invention provides direct experimental evidence for the application of the traditional Chinese medicine monomer luteolin in the medicines for preventing and treating endometriosis fibrosis.

Drawings

Figure 1 is the ectopic lesion volume change per rat.

FIG. 2 shows histological and pathological scores of the model group, the gestrinone group and the luteolin group.

FIG. 3 shows the relative degree of fibrosis between the pregnenone group and the luteolin group.

FIG. 4 shows the indexes of immunohistochemical detection of fibrosis in the model group, the gestrinone group and the luteolin group.

Detailed Description

The following examples are provided to illustrate specific embodiments of the present invention.